2
0This research article investigates how gemcitabine chemotherapy inadvertently fuels treatment resistance in pancreatic ductal adenocarcinoma by triggering cellular senescence. The authors demonstrate that senescent tumor cells release a specific secretory phenotype that activates fibroblasts, leading to a stiffened, fibrotic tumor environment. This mechanical change activates the Piezo1 ion channel, which drives a metabolic shift that protects cancer cells from oxidative damage and ferroptosis. Specifically, the study identifies the BRG1–NRF2–SLC7A11 signaling axis as a critical defense mechanism that tumor cells use to survive in these dense environments. To combat this, the researchers propose a triple-combination therapy—gemcitabine, a senolytic agent, and a ferroptosis inducer—to dismantle the stroma and restore drug sensitivity. Their findings suggest this approach can effectively suppress tumor growth and improve the efficacy of immunotherapy by remodeling the immune microenvironment.
References:
Liu X, Huang Z, Yang B, et al. Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma[J]. Nature Communications, 2026, 17: 8798.
